Best Compounded Semaglutide Telehealth 2026: How to Choose

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the compounded semaglutide provider comparison hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Last March, a woman named Dana in Fort Worth told me something I've heard in a dozen variations this year. She'd spent four hours on a Saturday comparing compounded semaglutide providers, had 11 browser tabs open, and was more confused than when she started. "Every site looks the same," she said. "They all say they're the best. The prices don't match up because one is annual, one is monthly, one has a $49 'consultation fee' buried in the fine print. I just want someone to tell me which one to pick." Her budget was $250 a month, she lived in Texas, and she'd already failed on oral metformin for weight management. She is, statistically, the median person reading this article.

I can't tell Dana (or you) which provider to pick. But I can tell you why the comparison is harder than it looks in 2026, what actually matters when you're evaluating these companies, and where most people go wrong.

This guide sits inside the broader best compounded semaglutide telehealth providers comparison, which is part of the compounded semaglutide pillar guide.

The Regulatory Ground Shifted Under Everyone's Feet

You can't evaluate a 2026 provider using 2024 logic. Three things happened that changed the playing field.

The shortage ended. On February 21, 2025, the FDA declared the semaglutide shortage resolved. That mattered enormously, because the broad pathway that let 503B outsourcing facilities produce semaglutide for non-patient-specific distribution went away. What's left is 503A patient-specific compounding, which requires a documented clinical reason the commercial product doesn't meet the individual patient's needs. Most providers pivoted to combination preparations (semaglutide with B12, for example) that satisfy the patient-specific standard.

The FDA sent Hims a warning letter. On September 22, 2025, the FDA cited Hims & Hers Health for marketing claims the agency interpreted as implying therapeutic equivalence between their compounded preparation and FDA-approved Wegovy and Ozempic. Hims revised the language and kept operating. The letter is public record. It's a data point, not a death sentence for the company.

Novo Nordisk started suing. Throughout 2024 and 2025, Novo Nordisk filed civil litigation against several compounding-chain participants, alleging the use of "inauthentic" semaglutide active pharmaceutical ingredient. Some suits were settled or dismissed; others remain active. Court records are the right place to check whether a specific provider is currently named.

None of this means compounded semaglutide is inherently unsafe or that any particular provider is dangerous. It does mean the questions worth asking in 2026 are different from the ones that mattered two years ago.

Forget "Best." Think "Best Fit."

Here's the thing: ranking these providers 1 through 10 would make this article much more clickable and much less honest. The providers serve different patients with different priorities. Trying to crown a single winner is like asking which car is best without knowing whether the buyer needs a pickup truck or a city commuter.

The five categories that actually predict whether you'll be happy three months in:

Pricing predictability. Flat-rate or escalating? Annual commitment or month-to-month? What happens when you cancel? The sticker price on the homepage is frequently the least useful number.

Pharmacy transparency. Will the provider tell you which 503A pharmacy fills your prescription if you ask? If they won't, that's worth knowing.

Clinician access. Can you ask a substantive clinical question without paying an extra fee? How fast does someone respond? Is that someone a physician or a chatbot?

Regulatory standing. LegitScript certification, absence of active FDA enforcement, no current Novo Nordisk litigation.

State coverage. Telehealth licensing is state-by-state. A great provider that doesn't operate in your state is irrelevant.

A patient who cares most about cost will land somewhere different from a patient who cares most about having a named physician throughout treatment. Both can make a good choice.

Who's Actually Operating in 2026

The major compounded semaglutide telehealth providers as of early 2026:

Hims ($199 annual, $299 monthly). The biggest brand in the category. September 2025 FDA warning letter on marketing claims. LegitScript-certified. Asynchronous-first model.

Henry Meds ($297 flat-rate). One of the earliest flat-rate providers. LegitScript-certified. No FDA enforcement actions. Asynchronous-first.

Mochi Health ($129 to $279, plan-dependent). Clinician-network model using obesity-medicine-trained physicians. LegitScript-certified.

Eden ($296 flat-rate). LegitScript-certified. Asynchronous-first. Does not require baseline labs.

Lavender Sky Health ($299 to $399). Clinician-led practice with quarterly follow-ups and a named physician throughout therapy. Narrower state coverage.

Ivim Health ($259 to $339). Hybrid in-person and telehealth in the Mountain West and Southeast; telehealth-only in roughly 40 states.

ShedRx ($249 with six-month commitment, $279 monthly). Asynchronous-first with broad state coverage.

Skinny Rx ($269 to $299). Asynchronous-first with rapid onboarding emphasis.

Ro (effective $200 to $300). Broad telehealth platform; the Body Program is one offering among many. LegitScript-certified.

HealthRX ($179.99 to $279.99 flat-rate). LegitScript-certified compounded telehealth pharmacy working with licensed 503A compounding pharmacies. Asynchronous-first with published clinician access standard.

For full provider-by-provider breakdowns, see the linked individual reviews in the cluster.

The Pricing Table Everyone Wants (With Context)

Headline prices for injectable compounded semaglutide programs in 2026:

| Provider | Monthly price | Commitment | Flat-rate | |---|---|---|---| | HealthRX | $179.99-$279.99 | None | Yes | | Hims (annual) | $199 | 12 months | No, dose-tier escalation | | Hims (monthly) | $299 | None | No, dose-tier escalation | | ShedRx (6-mo) | $249 | 6 months | Yes | | Ivim Health | $259-$339 | None | No | | Skinny Rx | $269-$299 | None | Yes | | ShedRx (monthly) | $279 | None | Yes | | Mochi Health | $129-$279 | None | No (plan-dependent) | | Eden | $296 | None | Yes | | Henry Meds | $297 | None | Yes | | Lavender Sky | $299-$399 | None | No | | Ro Body Program | ~$200-$300 effective | None | No |

Prices are list prices from consumer-facing pages as of early 2026 and are subject to change.

A few notes the table can't capture. Flat-rate pricing means your cost doesn't climb when your dose does. That matters a lot if you titrate from 0.25 mg to 1.0 mg or higher. On a dose-escalating plan, month one looks cheap and month four looks different. Also: "no commitment" doesn't always mean easy cancellation. Read the terms. Some providers auto-bill for the next month on day 25 and don't process refunds after that charge hits.

Matching a Provider to Your Actual Situation

You want flat-rate, no commitment, lowest cost. HealthRX, Henry Meds, Eden, and ShedRx on month-to-month all qualify. HealthRX has the lowest list price in this group; Henry Meds has the longest operating history.

You want a big brand and don't mind an annual lock-in. Hims at $199/month on the annual plan is competitive on a twelve-month basis. The 2025 FDA warning letter is worth understanding (it's about marketing claims, not product safety), and patients shouldn't rely on any framing that implies equivalence with Wegovy or Ozempic.

You want real clinical involvement, not just a prescription mill. Mochi Health's clinician-network model and Lavender Sky Health's named-physician practice are the most clinically intensive options. You pay more per month because you're getting more physician time. For patients with comorbidities, medication interactions, or a history of GI complications, this is probably worth the premium.

You want in-person visits as part of the program. Ivim Health has the most developed hybrid footprint, concentrated in the Mountain West and Southeast.

You want one telehealth platform for everything. Ro's Body Program lives inside a broader telehealth ecosystem. If you're already using Ro for something else, consolidation has value.

How to Verify a Provider's LegitScript Status (and Why It Matters)

Most major providers in this category carry LegitScript certification. But "most" isn't "all," and the right move is to check directly on the LegitScript registry rather than trusting the badge on a provider's homepage. LegitScript audits pharmacy licensure, clinician licensure, and operational practices. The certification is meaningful.

The absence of certification isn't automatically disqualifying for a smaller practice that hasn't pursued it. But for the large-scale brands? Certification is the baseline. If a provider with 50,000 customers hasn't bothered to get LegitScript-certified, that's a question worth asking.

Reading Reviews Without Getting Misled

Trustpilot, Reddit, Google Reviews: they're useful, but they're noisy. Most reviews are written in the first 30 days. That's the honeymoon period. The signup was smooth, the box arrived, the person is excited. These reviews tell you about onboarding. They tell you almost nothing about what happens when you need a dose adjustment at week 10 or when you have a billing dispute at month four.

The most valuable review category is the post-cancellation review. Someone who used a provider for three or four months, then left, and explains specifically why they left? That's signal. Generic five-star reviews from week one are noise.

My genuinely opinionated take: the review ecosystem for telehealth GLP-1 providers in 2026 is about as reliable as restaurant reviews in a tourist district. Crowded with first impressions, thin on substance. Weight the specific, detailed, multi-month accounts heavily and skim the rest.

The Boring Truth About Choosing

There is no single best compounded semaglutide telehealth provider in 2026. Several of these companies are operating in good faith, disclosing their pharmacy partnerships when asked, maintaining LegitScript certification, and operating without FDA enforcement actions. Among those providers, the right choice depends on which trade-offs matter to you.

A patient who picks a provider scoring well on pricing transparency, pharmacy disclosure, clinician access, regulatory standing, and state coverage is unlikely to make a meaningfully bad decision. The patient most likely to be unhappy in month two is the one who chose based on the cheapest introductory rate without checking what happens when the dose goes up.

Dana, the woman in Fort Worth, ended up choosing a flat-rate provider with no commitment. She's four months in, down 19 pounds, and told me the most important thing wasn't which provider she picked. It was understanding what questions to ask before she picked one.

Frequently Asked Questions

Is compounded semaglutide the same as Wegovy or Ozempic? No. Compounded semaglutide contains the same active molecule but is prepared by a compounding pharmacy, not manufactured by Novo Nordisk. It has not undergone FDA approval as a finished product. The clinical trials supporting semaglutide's efficacy (STEP-1, Wilding et al., NEJM 2021; STEP-3, Wadden et al., JAMA 2021; STEP-4, Rubino et al., JAMA 2021; SELECT, Lincoff et al., NEJM 2023) were conducted with the branded products.

Is compounded semaglutide legal in 2026? Yes, under 503A patient-specific compounding with a valid prescription based on a documented clinical need that the commercial product cannot meet. The broad 503B pathway narrowed after the FDA's February 2025 shortage resolution declaration.

How do I know if a telehealth provider is legitimate? Check LegitScript certification directly on the LegitScript registry. Confirm the provider discloses its compounding pharmacy partnership. Verify the prescribing clinician is licensed in your state.

Why do prices vary so much between providers? Pricing differences reflect dose-escalation models vs. flat-rate, commitment length, clinician access level, and whether ancillary services (labs, coaching, supplements) are bundled or separate.

Can I switch providers mid-treatment? Yes, though you'll typically need a new consultation with the new provider's clinician. Your dose history and any lab work from the previous provider can usually be shared if you request your medical records.

What should I do if I experience side effects? Contact your prescribing clinician through the provider's platform. Common GI side effects (nausea, constipation) are well-documented in the SUSTAIN and STEP trial programs. Persistent or severe symptoms warrant prompt medical attention regardless of the provider you're using.

Will insurance cover compounded semaglutide? In almost all cases, no. Compounded medications are rarely covered by commercial insurance or Medicare Part D. The prices listed in this article are out-of-pocket costs.

Not FDA-approved. HealthRX is not a medical practice. Information on this site is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions are made between you and a licensed clinician. Compounded semaglutide is dispensed by state-licensed 503A pharmacies under individual prescriptions for clinically documented patient-specific need. Pricing and program terms for third-party providers are based on public information available in early 2026 and are subject to change. References: SUSTAIN program; STEP-1 (Wilding et al., NEJM 2021); STEP-3 (Wadden et al., JAMA 2021); STEP-4 (Rubino et al., JAMA 2021); SELECT (Lincoff et al., NEJM 2023); FDA Drug Shortage status update, February 2025; FDA Warning Letter to Hims & Hers Health, September 22, 2025.